Calithera Biosciences Inc (CALA)

NASDAQ
1.920
+0.010(+0.52%)
After Hours
1.920
0.000(0.00%)
- Real-time Data
  • Volume:
    445,920
  • Bid/Ask:
    1.900/1.920
  • Day's Range:
    1.890 - 1.940

CALA Overview

Prev. Close
1.91
Day's Range
1.89-1.94
Revenue
3M
Open
1.91
52 wk Range
1.78-6.185
EPS
-1.12
Volume
445,920
Market Cap
141.56M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
534,217
P/E Ratio
-
Beta
1.57
1-Year Change
-47.54%
Shares Outstanding
74,114,399
Next Earnings Date
Nov 10, 2021
What is your sentiment on Calithera Biosciences Inc?
or
Market is currently closed. Voting is open during market hours.

Calithera Biosciences Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuySellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong SellStrong Sell

Calithera Biosciences Inc Company Profile

Calithera Biosciences Inc Company Profile

Employees
94

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company’s is engaged in discovering and development of targeted therapies, which disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. The Company is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. The Company’s principal operations are based in South San Francisco, California. It has a range of pipeline of small molecule drug candidates, which target enzymes controlling metabolically critical pathways in tumor cells and immune cells. It has multiple internally discovered clinical stage compounds that are all enzyme inhibitors. The Company is engaged in developing telaglenastat in combination with standard therapies in a select set of solid tumors. Its lead development pathway for telaglenastat is for the treatment of KEAP1 or NRF2 mutated non-small cell lung cancer (NSCLC).

Read More
  • this is very good. 👍🏼
    0
    • Who say????
      0
  • 4-5$ for one share is a good fair price for this company.
    0
    • Why? This is a pure speculation play.
      1
  • biotechnology stocks can move quickly. I bought for $ 2.77 in October 2019 and sold for $ 7.55 three months later. I hope for everyone who owns shares it goes back to $ 6.
    2
    • why dropping so much?
      0
      • when I bought it this was not news yet...but thanks
        0
    • is this going to 1 ?
      2
      • sold @7,55. good luck all
        0
        • Time to sell @ $4.10?
          0
          • Lets do it Susan Molineaux. Show good numbers
            0
            • Nice jump today. up to $4,- at the end of the year
              0
              • Buy more
                0
                • Buy
                  0
                  • I'm glad I didn't buy for 3.56. Now I'm in for $2.70
                    0
                • Time to buy CALA now for $3.56 at lowest point since 1 year?
                  1
                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.